Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 994.54 Million CNY | -2.99% |
| 2022 | 1.04 Billion CNY | 17.44% |
| 2021 | 891.09 Million CNY | 37.33% |
| 2020 | 648.88 Million CNY | 8.81% |
| 2019 | 596.34 Million CNY | 39.32% |
| 2018 | 428.04 Million CNY | 37.98% |
| 2017 | 310.22 Million CNY | 35.42% |
| 2016 | 229.08 Million CNY | 13.15% |
| 2015 | 202.46 Million CNY | 40.95% |
| 2014 | 143.64 Million CNY | 26.55% |
| 2013 | 113.5 Million CNY | 15.16% |
| 2012 | 98.56 Million CNY | 26.19% |
| 2011 | 78.1 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 252.41 Million CNY | -14.87% |
| 2024 Q3 | 268.98 Million CNY | -0.78% |
| 2024 Q2 | 275.62 Million CNY | 9.19% |
| 2023 FY | 1.01 Billion CNY | -2.99% |
| 2023 Q4 | 296.49 Million CNY | 37.9% |
| 2023 Q3 | 215.01 Million CNY | -19.61% |
| 2023 Q1 | 236.25 Million CNY | -34.58% |
| 2023 Q2 | 267.44 Million CNY | 13.2% |
| 2022 Q3 | 247.14 Million CNY | 3.93% |
| 2022 FY | 1.04 Billion CNY | 17.44% |
| 2022 Q2 | 237.78 Million CNY | 18.62% |
| 2022 Q1 | 200.46 Million CNY | -45.11% |
| 2022 Q4 | 361.11 Million CNY | 46.12% |
| 2021 FY | 891.09 Million CNY | 37.33% |
| 2021 Q1 | 166.07 Million CNY | -32.09% |
| 2021 Q4 | 365.2 Million CNY | 64.48% |
| 2021 Q3 | 222.03 Million CNY | 61.16% |
| 2021 Q2 | 137.77 Million CNY | -17.04% |
| 2020 Q4 | 244.55 Million CNY | 42.71% |
| 2020 Q3 | 171.36 Million CNY | 35.78% |
| 2020 FY | 648.88 Million CNY | 8.81% |
| 2020 Q1 | 106.74 Million CNY | -53.87% |
| 2020 Q2 | 126.21 Million CNY | 18.24% |
| 2019 Q1 | 107.57 Million CNY | -29.67% |
| 2019 Q2 | 112.83 Million CNY | 4.89% |
| 2019 Q4 | 231.42 Million CNY | 60.14% |
| 2019 FY | 596.34 Million CNY | 39.32% |
| 2019 Q3 | 144.51 Million CNY | 28.08% |
| 2018 Q4 | 152.96 Million CNY | 49.86% |
| 2018 Q2 | 95.35 Million CNY | 22.79% |
| 2018 Q1 | 77.65 Million CNY | -29.75% |
| 2018 FY | 428.04 Million CNY | 37.98% |
| 2018 Q3 | 102.07 Million CNY | 7.05% |
| 2017 Q4 | 110.54 Million CNY | 47.37% |
| 2017 Q1 | 55.86 Million CNY | -22.63% |
| 2017 FY | 310.22 Million CNY | 35.42% |
| 2017 Q2 | 68.79 Million CNY | 23.13% |
| 2017 Q3 | 75.01 Million CNY | 9.04% |
| 2016 Q2 | 53.97 Million CNY | 6.84% |
| 2016 FY | 229.08 Million CNY | 13.15% |
| 2016 Q4 | 72.21 Million CNY | 37.86% |
| 2016 Q3 | 52.38 Million CNY | -2.96% |
| 2016 Q1 | 50.52 Million CNY | -25.21% |
| 2015 FY | 202.46 Million CNY | 40.95% |
| 2015 Q4 | 67.55 Million CNY | 26.9% |
| 2015 Q3 | 53.23 Million CNY | 16.56% |
| 2015 Q2 | 45.66 Million CNY | 26.84% |
| 2015 Q1 | 36 Million CNY | 0.0% |
| 2014 FY | 143.64 Million CNY | 26.55% |
| 2013 FY | 113.5 Million CNY | 15.16% |
| 2012 FY | 98.56 Million CNY | 26.19% |
| 2011 FY | 78.1 Million CNY | 0.0% |